<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Berenson, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Reviews in Oncology/Hematology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bisphosphonate</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone lesion</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone pain</style></keyword><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Skeletal morbidity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951821906&amp;doi=10.1016%2fS1040-8428%2811%2970004-X&amp;partnerID=40&amp;md5=24540cab442f684ce03d515b32dea2f6</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">77</style></volume><pages><style face="normal" font="default" size="100%">S13 - S23</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Patients with advanced multiple myeloma (MM) often have increased osteolytic activity of osteoclasts and impaired osteogenesis by osteoblasts, resulting in osteolytic bone lesions that increase the risk of skeletal-related events (SREs) including pathologic fracture, the need for radiotherapy or surgery to bone, and spinal cord compression. Such SREs are potentially life-limiting, and can reduce patients' functional independence and quality of life. Bisphosphonates (e.g., oral clodronate and intravenous pamidronate and zoledronic acid) can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM. Extensive clinical experience demonstrates that bisphosphonates are generally well tolerated, and common adverse events are typically mild and manageable. Studies are ongoing to optimize the timing and duration of bisphosphonate therapy in patients with bone lesions from MM. © 2011 Elsevier Ireland Ltd.</style></abstract><issue><style face="normal" font="default" size="100%">SUPPL.1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :20Export Date: 21 February 2017</style></notes></record></records></xml>